Guardant Health - GH Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GH shares.
View GH analyst ratings or view top-rated stocks.

16 Wall Street research analysts have issued 12-month target prices for Guardant Health's shares. Their GH share price forecasts range from $36.00 to $165.00. On average, they expect the company's share price to reach $89.00 in the next twelve months. This suggests a possible upside of 211.6% from the stock's current price.
View analysts price targets for GH or view top-rated stocks among Wall Street analysts.

Guardant Health's stock was trading at $27.20 on January 1st, 2023. Since then, GH stock has increased by 5.0% and is now trading at $28.56.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our GH earnings forecast.

Guardant Health will be holding an earnings conference call on Thursday, February 23rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $0.16. The company earned $94.80 million during the quarter, compared to analysts' expectations of $92.59 million. Guardant Health had a negative trailing twelve-month return on equity of 145.58% and a negative net margin of 140.58%. The company's revenue for the quarter was up 26.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.78) EPS.

Guardant Health issued an update on its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $447.00 million-$450.00 million, compared to the consensus revenue estimate of $445.24 million.

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

(GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (0.49%), New York State Common Retirement Fund (0.24%), State Board of Administration of Florida Retirement System (0.11%), Sicart Associates LLC (0.10%), TD Asset Management Inc (0.09%) and Sumitomo Mitsui Trust Holdings Inc. (0.08%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends.

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GH stock can currently be purchased for approximately $28.56.

Guardant Health (NASDAQ:GH) has a market capitalization of $2.93 billion and generates $373.65 million in revenue each year. The company earns $-405,670,000.00 in net income (profit) each year or ($5.93) on an earnings per share basis.

The company employs 1,373 workers across the globe.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.